Gables Capital Management’s Lexaria Bioscience LEXX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-1
Closed -$7 – 511
2026
Q2
$7 Hold
1
– – ﹤0.01% 507
2026
Q1
$10 Hold
1
– – ﹤0.01% 471
2025
Q4
$8 Hold
1
– – ﹤0.01% 463
2025
Q3
$12 Hold
1
– – ﹤0.01% 457
2025
Q2
$11 Hold
1
– – ﹤0.01% 442
2025
Q1
$22 Hold
1
– – ﹤0.01% 442
2024
Q4
$27 Hold
1
– – ﹤0.01% 443
2024
Q3
$40 Hold
1
– – ﹤0.01% 443
2024
Q2
$36 Hold
1
– – ﹤0.01% 394
2024
Q1
$47 Hold
1
– – ﹤0.01% 388
2023
Q4
$16 Hold
1
– – ﹤0.01% 377
2023
Q3
$13 Buy
+1
New +$14 ﹤0.01% 363
2023
Q2
– Sell
-1
Closed -$35 – 379
2023
Q1
$35 Hold
1
– – ﹤0.01% 374
2022
Q4
$32 Hold
1
– – ﹤0.01% 358
2022
Q3
$0 Hold
1
– – ﹤0.01% 346
2022
Q2
$0 Hold
1
– – ﹤0.01% 354
2022
Q1
$0 Hold
1
– – ﹤0.01% 349
2021
Q4
$0 Hold
1
– – ﹤0.01% 354
2021
Q3
$0 Buy
+1
New +$96 ﹤0.01% 358

Other funds holding LEXX

Gables Capital Management's LEXX Position: Q3 2026 in Review

Gables Capital Management sold out of Lexaria Bioscience (LEXX) in Q3 2026, closing a stake of 1 share — an estimated $7 sold.

Gables Capital Management first reported a position in LEXX in Q3 2021 and held it in 19 quarters. The position peaked at $47 in Q1 2024. 15 funds tracked by Wall St. Rank hold LEXX as of Q3 2026.

  • Gables Capital Management reported no remaining Lexaria Bioscience position as of Q3 2026 after selling out during the quarter.
  • Gables Capital Management sold 1 Lexaria Bioscience share in Q3 2026, an estimated $7.
  • Gables Capital Management first reported a position in Lexaria Bioscience in Q3 2021 and held it in 19 quarters.
  • Gables Capital Management's Lexaria Bioscience position peaked at $47 in Q1 2024.
  • 15 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q3 2026.

Based on Gables Capital Management's 13F filing for Q3 2026, filed 4 Nov 2026.